Cargando…
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
BACKGROUND: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcomes in men with nonmetastatic castration-resistant...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767934/ https://www.ncbi.nlm.nih.gov/pubmed/33425798 http://dx.doi.org/10.1016/j.prnil.2020.05.002 |
_version_ | 1783629071882649600 |
---|---|
author | Uemura, Hiroji Satoh, Takefumi Tsumura, Hideyasu Arai, Gaku Imanaka, Keiichiro Shibayama, Kazuhiro Fujii, Koji Rooney, Brendan Lopez-Gitlitz, Angela Espina, Byron Perez-Ruixo, Carlos Small, Eric J. Smith, Matthew |
author_facet | Uemura, Hiroji Satoh, Takefumi Tsumura, Hideyasu Arai, Gaku Imanaka, Keiichiro Shibayama, Kazuhiro Fujii, Koji Rooney, Brendan Lopez-Gitlitz, Angela Espina, Byron Perez-Ruixo, Carlos Small, Eric J. Smith, Matthew |
author_sort | Uemura, Hiroji |
collection | PubMed |
description | BACKGROUND: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcomes in men with nonmetastatic castration-resistant prostate cancer (nm-CRPC) who were at high risk of developing metastases. In this subpopulation analysis of Selective Prostate Androgen Receptor Targeting with ARN-509 study, the efficacy and safety of apalutamide plus ADT were evaluated in Japanese patients with nm-CRPC. METHODS: The primary efficacy end point was MFS. Secondary efficacy end points were time to metastasis, progression-free survival, symptomatic progression, initiation of cytotoxic chemotherapy, and overall survival. Safety and pharmacokinetic parameters were also assessed. RESULTS: Fifty-five Japanese patients with ongoing ADT were randomized (apalutamide: n = 34, placebo: n = 21). Median treatment duration was 5.7 months in the apalutamide group and 11.0 months in the placebo group. Median MFS was not reached in the apalutamide group (95% confidence interval: 10.97, not estimable) and was 18.23 months (95% confidence interval: 11.04, 18.50) in the placebo group. Secondary end points were improved in the apalutamide group. The safety profile of apalutamide with ADT was comparable with the global population, and no new safety signals were identified in this Japanese subpopulation. Although, apalutamide exposure tended to be higher in the Japanese subpopulation compared with the non-Japanese population, this was likely to be explained by body weight and considered not clinically meaningful. CONCLUSION: In the Japanese subpopulation, treatment with apalutamide with ADT resulted in favorable efficacy outcomes with comparable benefit-risk profile to the global population with nm-CRPC who are at high-risk of developing metastases. |
format | Online Article Text |
id | pubmed-7767934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Asian Pacific Prostate Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-77679342021-01-07 Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study Uemura, Hiroji Satoh, Takefumi Tsumura, Hideyasu Arai, Gaku Imanaka, Keiichiro Shibayama, Kazuhiro Fujii, Koji Rooney, Brendan Lopez-Gitlitz, Angela Espina, Byron Perez-Ruixo, Carlos Small, Eric J. Smith, Matthew Prostate Int Research Article BACKGROUND: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcomes in men with nonmetastatic castration-resistant prostate cancer (nm-CRPC) who were at high risk of developing metastases. In this subpopulation analysis of Selective Prostate Androgen Receptor Targeting with ARN-509 study, the efficacy and safety of apalutamide plus ADT were evaluated in Japanese patients with nm-CRPC. METHODS: The primary efficacy end point was MFS. Secondary efficacy end points were time to metastasis, progression-free survival, symptomatic progression, initiation of cytotoxic chemotherapy, and overall survival. Safety and pharmacokinetic parameters were also assessed. RESULTS: Fifty-five Japanese patients with ongoing ADT were randomized (apalutamide: n = 34, placebo: n = 21). Median treatment duration was 5.7 months in the apalutamide group and 11.0 months in the placebo group. Median MFS was not reached in the apalutamide group (95% confidence interval: 10.97, not estimable) and was 18.23 months (95% confidence interval: 11.04, 18.50) in the placebo group. Secondary end points were improved in the apalutamide group. The safety profile of apalutamide with ADT was comparable with the global population, and no new safety signals were identified in this Japanese subpopulation. Although, apalutamide exposure tended to be higher in the Japanese subpopulation compared with the non-Japanese population, this was likely to be explained by body weight and considered not clinically meaningful. CONCLUSION: In the Japanese subpopulation, treatment with apalutamide with ADT resulted in favorable efficacy outcomes with comparable benefit-risk profile to the global population with nm-CRPC who are at high-risk of developing metastases. Asian Pacific Prostate Society 2020-12 2020-05-28 /pmc/articles/PMC7767934/ /pubmed/33425798 http://dx.doi.org/10.1016/j.prnil.2020.05.002 Text en © 2020 Asian Pacific Prostate Society. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Uemura, Hiroji Satoh, Takefumi Tsumura, Hideyasu Arai, Gaku Imanaka, Keiichiro Shibayama, Kazuhiro Fujii, Koji Rooney, Brendan Lopez-Gitlitz, Angela Espina, Byron Perez-Ruixo, Carlos Small, Eric J. Smith, Matthew Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title | Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title_full | Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title_fullStr | Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title_full_unstemmed | Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title_short | Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study |
title_sort | efficacy and safety of apalutamide in japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase-3 study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767934/ https://www.ncbi.nlm.nih.gov/pubmed/33425798 http://dx.doi.org/10.1016/j.prnil.2020.05.002 |
work_keys_str_mv | AT uemurahiroji efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT satohtakefumi efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT tsumurahideyasu efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT araigaku efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT imanakakeiichiro efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT shibayamakazuhiro efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT fujiikoji efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT rooneybrendan efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT lopezgitlitzangela efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT espinabyron efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT perezruixocarlos efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT smallericj efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study AT smithmatthew efficacyandsafetyofapalutamideinjapanesepatientswithnonmetastaticcastrationresistantprostatecancerasubgroupanalysisofarandomizeddoubleblindplacebocontrolledphase3study |